Welcome to our dedicated page for Inogen news (Ticker: INGN), a resource for investors and traders seeking the latest updates and insights on Inogen stock.
Inogen Inc (INGN) is a pioneering medical technology company specializing in portable oxygen concentrators for respiratory care. This dedicated news hub provides investors and healthcare professionals with essential updates on product developments, regulatory milestones, and strategic initiatives.
Access timely announcements including quarterly earnings reports, FDA clearances for new devices, partnership agreements with healthcare providers, and clinical study results. Our curated collection ensures you stay informed about innovations in oxygen therapy technology and market expansion efforts.
Key focus areas include advancements in lightweight oxygen systems, international distribution updates, and operational developments impacting respiratory patient care. Bookmark this page for direct access to primary source materials and analyzed updates from INGN's corporate communications.
Sommetrics, focused on enhancing sleep health, reported key Q1 2022 achievements, notably advancing clinical activities for FDA clearance of aerSleep® II, a non-invasive treatment for obstructive sleep apnea. The six-month SUPRA pivotal trial is ongoing at various U.S. sleep centers, with promising safety data. Recent patent approvals in the U.S. and Japan bolster its intellectual property, totaling 36 patents. The company is targeting $16 million in its Series C financing, raising $11 million so far. Scott Wilkinson, former Inogen CEO, has been appointed as Advisor to guide aerSleep® II's market entry.
Inogen, Inc (NASDAQ: INGN) announced its first quarter 2022 financial results will be released after market close on
Inogen, a medical technology company specializing in homecare respiratory products, announced its participation in the 21st Annual Needham Virtual Healthcare Conference. CEO Nabil Shabshab and CFO Kristin Caltrider are set to present on April 13, 2021, at 12:45 p.m. ET. Interested parties can access the live webcast on Inogen's Investor Relations page. The presentation will be available for replay for 90 days following the event. Inogen is known for developing portable oxygen concentrators aimed at patients with chronic respiratory conditions.
Inogen, Inc. (NASDAQ: INGN) announced participation in the KeyBanc Life Sciences & MedTech Investor Forum on March 23, 2022, at 4:30 p.m. ET. The company's President and CEO, Nabil Shabshab, and CFO, Kristin Caltrider, will present at the event. A webcast will be available on the Inogen Investor Relations website, with a replay accessible for 90 days post-presentation. Inogen specializes in developing and marketing portable oxygen concentrators for chronic respiratory conditions, aiming to enhance homecare solutions for patients.
Inogen, Inc. (NASDAQ: INGN) appointed Kristin Caltrider as EVP & Chief Financial Officer, effective March 21, 2022, succeeding interim CFO Mike Sergesketter. Nabil Shabshab, CEO, expressed confidence in Caltrider's proven experience in healthcare financial operations. Caltrider previously served as Vice President of Finance at Quidel Corporation. She aims to leverage Inogen's strong talent base and strategic plan for sustainable growth. The transition aims for smooth continuity as the company seeks to enhance its position in the respiratory care MedTech sector.
Inogen, Inc. (NASDAQ: INGN) reported Q4 2021 total revenue of $76.4 million, a 3.3% year-over-year increase. Domestic direct-to-consumer revenue rose 23.3% to $33.0 million, while rental revenue surged 39.4% to $13.0 million. Full-year revenue reached $358.0 million, up 16.1% from 2020. Adjusted EBITDA for Q4 was ($0.5 million) with a net loss of $22.9 million. Supply chain challenges, especially regarding semiconductor availability, are expected to impact operations in 2022. The company anticipates mid-single-digit revenue growth for the year, with negative EBITDA and operating losses projected for Q1 2022.
Inogen, Inc. (NASDAQ: INGN) will release its fourth quarter 2021 financial results after market close on February 24, 2022. A conference call is scheduled for 2:00 PM PT / 5:00 PM ET to discuss the results. Interested parties can listen by calling (877) 841-3961 for domestic and (201) 689-8589 for international callers. A replay will be available starting at 4:00 PM PT on the same day until March 10, 2022. More information is accessible via their Investor Relations website.
Inogen, Inc. (NASDAQ: INGN) announced preliminary Q4 2021 revenue between
Gelesis has appointed
Inogen, Inc. (NASDAQ: INGN) announced the election of Elizabeth Mora as Board Chairperson, succeeding Heath Lukatch, who will remain on the Board. Ray Huggenberger is retiring from the Board after serving since 2008 but will transition to an advisory role. Mora, who joined the Board in May 2021, will also chair the Compliance Committee. The Board has been reduced to seven members. Leadership changes aim to enhance Inogen's strategic goals in respiratory care. Future performance remains uncertain due to market risks and competition.
